Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified “Dutch Auction” tender offer (the “Offer”) to repurchase up to US$230 million of its common shares at a purchase price of not less […]
Financial Post
First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on .
Signal breakdown
CurrentWire ranked this story 60.2 of 100 in the snapshot this page was rendered from.
- Freshness
- 32.7 of 35
- Source authority
- 7 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 10 of 10
- Story prominence
- 6.5 of 10
- Velocity
- 0 of 5
Strongest signal: geographic relevance, 10 of 10. How each signal is calculated.
Filed under Business · United States · Press release. Topics extracted from this report, with other live CurrentWire stories mentioning each: Repurchase Up (none), Common Shares Through Modified Dutch Auction Tender Offer (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.